E
GBIO

Ergoteles’s Generation Bio GBIO Stock Holding History

Ergoteles’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,509
Closed -$64.9K – 1196
2023
Q1 		$64.9K Buy
+1,509
New +$73K ﹤0.01% 1123
2022
Q3 		– Sell
-4,455
Closed -$292K – 1693
2022
Q2 		$292K Buy
+4,455
New +$291K 0.01% 1121

Other funds holding GBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ergoteles's GBIO Position: Q2 2023 in Review

Ergoteles sold out of Generation Bio (GBIO) in Q2 2023, closing a stake of 1,509 shares — an estimated $64.9K sold.

Ergoteles first reported a position in GBIO in Q2 2022 and held it in 2 quarters. The position peaked at $292K in Q2 2022. 79 funds tracked by Wall St. Rank hold GBIO as of Q2 2023.

  • Ergoteles reported no remaining Generation Bio position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 1,509 Generation Bio shares in Q2 2023, an estimated $64.9K.
  • Ergoteles first reported a position in Generation Bio in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Generation Bio position peaked at $292K in Q2 2022.
  • 79 funds tracked by Wall St. Rank held Generation Bio as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.